Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study.
Elisa Hernández-Álvarez, Lucas F Borkel, Jaime Rojas-Hernández, Domingo J Quintana-Hernández, Ignacio García-Serrano, Tobías Fernández-Borkel, Manuel Zumbado, Luis Alberto Henríquez-Hernández
Veterinary medicine and science July 1, 2025 DOI: 10.1002/vms3.70486 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pilot study, single-case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 13-year-old female dog with severe separation anxiety |
| Intervention | 1cp-LSD |
| Dose | 5 µg every 3 days |
| Duration | 1-month treatment, 1-month follow-up |
| Topics | Anxiety LSD Microdosing |
| Keywords | 1cp‐LSD Animal behaviour Animal consciousness Dogs Microdosing: microdosing Psychedelic microdosing Dog anxiety Animal anxiety Psychedelics: psychedelics 1cp-LSD Psychedelic compounds Dog behavior |
| Citations | 3 |
| Key findings | Microdosing 1cp-LSD was associated with a reduction in canine anxiety scores from severe to moderate, but the absence of a control group limits causal interpretation. |
Abstract
This pilot study explored the potential of microdosing 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) to treat canine anxiety. A single-case study was conducted on a 13-year-old female dog with severe separation anxiety, who was treated with 5 µg of 1cp-LSD every 3 days for a month. Anxiety was assessed before, after, and 1 month following treatment using a validated questionnaire. The owner's attachment style was assessed using a validated scale. The dog's anxiety score significantly decreased from 29 (severe) to 14 (moderate) after treatment. A reduction in anxiety levels was observed, characterized by decreased destructive behaviour and shorter durations of vocalization. This improvement was sustained 1 month following treatment, although vocalization frequency increased. These findings suggest potential therapeutic efficacy of microdosing 1cp-LSD in managing canine anxiety; however, the absence of a control group makes it difficult to determine whether the observed effects are due to 1cp-LSD, owner bias, or natural variability in the dog's behaviour. Additional studies with blinded protocols and larger sample sizes are necessary to validate these findings and further explore the impact of owner attachment on canine anxiety.
Comparable studies
Other non-randomized and open-label trials on LSD and microdosing, most cited first.